Company’s web-based platform empowers researchers to integrate, process, and visualize biological data in one place, shortening timelines from experiment to results

June 02, 2022 10:00 AM Eastern Daylight Time

SAN FRANCISCO--(BUSINESS WIRE)--LatchBio, a company accelerating the pace of scientific progress by enabling researchers to store and analyze data without touching code or cloud infrastructure, today announced a $28 million Series A round co-led by Coatue and existing investor Lux Capital. Hummingbird Ventures, Caffeinated Capital, and existing investors Haystack and Fifty Years also participated.

The LatchBio platform is a streamlined web-based solution designed to overcome bottlenecks in biotech research caused by the massive datasets generated by modern experiments. Using any browser, researchers can quickly import files from existing data stacks and access dozens of popular bioinformatics pipelines and data visualization tools including RNA-Seq, CRISPResso2 and AlphaFold. As bioinformaticians upload workflows via the LatchBio SDK, no-code interfaces are automatically created for biologists who are now empowered to integrate, process, and visualize data in one place. Experiment data can be stored and processed at any scale using serverless data infrastructure, significantly reducing the time and resources required to get from experiment to insight.

Scientists at leading industry organizations including the Innovative Genomics Institute (IGI), BitBio and Eligo Bioscience are leveraging the power of the LatchBio platform to advance their work.

“The datasets generated by today’s scientific experiments are growing at an exponential rate, but many biologists lack the computational tools they need to rapidly analyze and iterate using the results of their experiments,” said Coatue General Partner David Cahn. “Coatue looks forward to supporting LatchBio’s ambition to create the necessary infrastructure to hasten the pace of discovery and translational research – and importantly help get more life-saving therapies into the clinic.”

“Since leading LatchBio’s seed round, we have been impressed by the dedication, focus and speed with which the team is building solutions that will make a meaningful impact on the way science is done in the lab every day,” said Lux Capital Partner Brandon Reeves. “We are pleased to once again back this team of founders and their vision to address some of the computational and logistical challenges facing those working at the cutting edge of science.”

“The Latch team is extremely proud to be backed by experienced investors who believe in our mission to build tools that accelerate humanity's ability to engineer biology,” said Alfredo Andere, co-founder and CEO of LatchBio. “We remain obsessively focused on building a platform that hosts the best biocomputing workflows and other tools that scientists love to use and that enable them to accelerate scientific progress.”

About LatchBio

LatchBio is a San Francisco-based company on a mission to build and disseminate the data infrastructure for the biocomputing revolution. The company’s cloud-based platform offers no-code bioinformatics for scientists seeking to store, transform and visualize their data. Through any web browser, the global scientific community can quickly access popular bioinformatics pipelines and data visualization tools. For company updates, visit latch.bio.

Contacts

Thermal for LatchBio
Tate LaCasse
media@latch.bio

https://www.businesswire.com/news/home/20220602005373/en/LatchBio-Raises-28M-Series-A-to-Bring-a-Modern-Data-Analysis-Stack-to-Biologists

‍